{"slideshow_credits": null, "snippet": "Filings show that under a one-time stock grant created in 2014, top executives stand to reap riches at least partly on the back of price increases on the EpiPen....", "abstract": "Gretchen Morgenson Fair Game column describes how executives at pharmaceutical giant Mylan stand to profit from excessive pricing of its EpiPen allergy treatment; observes connection between treatment's unusual price rise and company's announcement of one-time stock grant that will lavishly reward executives if earnings and stock price meet certain goals by end of 2018; notes irregularities in Mylan's account of its earnings.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Gretchen", "role": "reported", "lastname": "MORGENSON", "rank": 1, "organization": ""}], "original": "By GRETCHEN MORGENSON"}, "web_url": "http://www.nytimes.com/2016/09/04/business/at-mylan-lets-pretend-is-more-than-a-game.html", "lead_paragraph": "Filings show that under a one-time stock grant created in 2014, top executives stand to reap riches at least partly on the back of price increases on the EpiPen.", "headline": {"print_headline": "EpiPen Soars and So Does Bosses\u2019 Pay", "main": "EpiPen Price Rises Could Mean More Riches for Mylan Executives", "content_kicker": "Fair Game", "kicker": "Fair Game"}, "_id": "57c867ac95d0e021d7983dd3", "word_count": "1199", "multimedia": [{"height": 126, "url": "images/2016/09/02/business/02GRET/02GRET-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/09/02/business/02GRET/02GRET-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2016/09/02/business/02GRET/02GRET-articleLarge.jpg", "legacy": {"xlarge": "images/2016/09/02/business/02GRET/02GRET-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/09/02/business/02GRET/02GRET-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/02/business/02GRET/02GRET-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-09-01T17:38:46+0000", "source": "The New York Times", "news_desk": "SundayBusiness", "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "1"}, {"name": "persons", "value": "Bresch, Heather", "is_major": "N", "rank": "2"}, {"name": "organizations", "value": "Mylan Inc", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Executive Compensation", "is_major": "Y", "rank": "4"}, {"name": "organizations", "value": "Abbott Laboratories", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "7"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "8"}, {"name": "subject", "value": "Allergies", "is_major": "Y", "rank": "9"}], "blog": [], "subsection_name": null, "type_of_material": "News"}